Artimplant Employs New Marketing Manager

The biomaterials company Artimplant (STO:ARTIB), employs Kauko Haapasaari as new Marketing Manager. Mr Haapasaari will assume his new responsibility on October 1st.

Mr Haapasaari is presently director of business development at Raisio Diagnostics. He has previously held marketing and sales positions at Conpharm, SP-Maskiner, Swedish Trade Council, Instrument Lambda and KabiVitrum.

Kauko Haapasaari holds a B.Sc in Chemical and Administrative Sciences and brings to Artimplant more than 24 years of experience in the life science business.

"I have the highest expectations when bringing my knowledge and experience to Artimplant. I believe that my successful sales and marketing career within the life science industry will be an excellent platform for my tasks at Artimplant. I look forward to working with the healthcare providers to make them embrace the biomaterial Artelon(R) to improve the quality of life among their patients," says Kauko Haapasaari.

Hans Rosen, CEO of Artimplant comments: "It's with great pleasure we welcome Kauko, with his solid background, to the Artimplant team. We will benefit from his intimate experience of international marketing and sales within the life science industry. Mr Haapasaari will be responsible for the marketing and sales of Artimplant's products."

About Artimplant Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production, and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon(R), meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This information was brought to you by Cision http://newsroom.cision.com